Anna Carbone
Lodi, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Retraction notice to "Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammatin" [European Journal of Pharmaceutical Sciences 51C (2013) 26-33].
Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Published: September 08, 2018
Retraction notice to "Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients" [Pharmacol. Res. 73 (2013) 20-26].
Journal: Pharmacological research
Published: June 13, 2017
Retraction notice to "Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies": J Am Soc Hypertens 7 (2013) 32-39.
Journal: Journal of the American Society of Hypertension : JASH
Published: October 01, 2015
Retraction Note to: Different Aspects of Sartan + Calcium Antagonist Association Compared to the Single Therapy on Inflammation and Metabolic Parameters in Hypertensive Patients.
Journal: Inflammation
Published: August 05, 2015
Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin.
Journal: Internal medicine (Tokyo, Japan)
Published: October 04, 2013
Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients.
Journal: Inflammation
Published: September 11, 2013
Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy.
Journal: Canadian journal of physiology and pharmacology
Published: August 30, 2013
Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies.
Journal: Expert opinion on drug safety
Published: July 03, 2013
Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.
Journal: Pharmacotherapy
Published: June 08, 2013
RETRACTED: Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients.
Journal: Pharmacological research
Published: March 02, 2013
Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation.
Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Published: February 23, 2013
A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study.
Journal: Diabetes technology & therapeutics
Published: February 23, 2013
Last Updated: 09/26/2026